ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 95 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,008,637 | -45.2% | 50,281 | -23.0% | 0.00% | -100.0% |
| Q2 2023 | $1,842,141 | +129.1% | 65,301 | +39.7% | 0.00% | – |
| Q1 2023 | $804,221 | +1173.3% | 46,757 | +1391.0% | 0.00% | – |
| Q4 2022 | $63,160 | -48.2% | 3,136 | -44.7% | 0.00% | – |
| Q3 2022 | $122,000 | -90.8% | 5,669 | -88.0% | 0.00% | – |
| Q2 2022 | $1,323,000 | -77.7% | 47,083 | -63.3% | 0.00% | -100.0% |
| Q1 2022 | $5,924,000 | -45.8% | 128,418 | -1.2% | 0.00% | -33.3% |
| Q4 2021 | $10,925,000 | -66.9% | 129,980 | -73.8% | 0.00% | -57.1% |
| Q3 2021 | $33,035,000 | +22.4% | 495,731 | -2.3% | 0.01% | +16.7% |
| Q2 2021 | $26,983,000 | +16057.5% | 507,196 | +13050.0% | 0.01% | – |
| Q1 2021 | $167,000 | -80.9% | 3,857 | -77.1% | 0.00% | – |
| Q4 2020 | $876,000 | +217.4% | 16,865 | +99.6% | 0.00% | – |
| Q3 2020 | $276,000 | +9.5% | 8,450 | +61.1% | 0.00% | – |
| Q2 2020 | $252,000 | – | 5,245 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |